

July 07, 2026

National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai-400051

BSE Limited
Phiroze Jeejeebhoy Towers, Dalal
Street Fort, Mumbai- 400001

Symbol: **ORCHPHARMA**

Scrip Code: **524372**

Subject: Announcement under Regulation 30 regarding the licensing and supply agreement with Pharmasintez JSC, Russia

Dear Sir/Madam,

In accordance to Regulation 30 read with Part A of Schedule III of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, this is to inform that the Company has entered into a licensing and supply agreement with Pharmasintez JSC, Russia. Kindly find the enclosed the Press Release dated July 07, 2026 titled as "**Orchid Pharma Signs Licensing and Supply Agreement with Pharmasintez to Commercialize Exblifep® (Cefepime/Enmetazobactam) in Russia.**"

You are requested to take the above information on record.

Thanking You,

For **Orchid Pharma Limited**

Kapil Dayya
Company Secretary & Compliance Officer
Membership No.: F10698

Encl: As Above

7th July 2026

Orchid Pharma Signs Licensing and Supply Agreement with Pharmasintez to Commercialize Exblifep® (Cefepime/Enmetazobactam) in Russia

Orchid Pharma Ltd. (Orchid) and Pharmasintez JSC (Pharmasintez) have entered into a licensing and supply agreement for Exblifep® (cefepime/enmetazobactam), a novel combination antibiotic for the treatment of complicated urinary tract infections (cUTI) and hospital-acquired and ventilator-associated bacterial pneumonia (HAP/VAP) caused by Gram-negative bacterial pathogens, subject to regulatory approval by the Ministry of Health of the Russian Federation.

Exblifep is a carbapenem-sparing antibiotic developed to address the growing clinical challenge posed by ESBL-producing Gram-negative bacteria in serious hospital infections. The product is approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), is included in IDSA and EUCAST treatment guidelines, and is the first new chemical entity originating from an Indian pharmaceutical company to receive both approvals.

Under the agreement, Pharmasintez will hold the exclusive rights to register and commercialize Exblifep in Russia, with Orchid supplying the finished dosage form. **The partnership represents a potential opportunity of approximately USD 178 million over the first 10 years**, reflecting the scale of unmet clinical need and the significant hospital procurement volumes in the Russian market.

"Our partnership with Pharmasintez marks an important step in making Exblifep available to patients in Russia. Pharmasintez's deep reach into the Russian hospital procurement system makes them the right partner to ensure this medicine gets to the clinicians and patients who need it." — **Manish Dhanuka, Managing Director, Orchid Pharma Ltd.**

"Antimicrobial resistance is one of the most significant challenges facing modern medicine, making the development of new antibiotics critical. Orchid Pharma has met this challenge by developing the novel antibiotic Exblifep® (cefepime/enmetazobactam). This licensing agreement with Pharmasintez enables Russian patients to gain access to modern antibacterial therapy." said **Natalia Malykh, Vice President of Business Development at the Pharmasintez group.**

About Orchid Pharma Limited

Orchid Pharma Limited is a fully vertically integrated pharmaceutical company with end-to-end capabilities from Key Starting Materials (KSMs) to Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs), focused on complex injectable antibiotics. Orchid is the first Indian pharmaceutical company to invent a New Chemical Entity (NCE) approved in both the United States and Europe, with the product commercially marketed in Europe and India. The company operates globally approved manufacturing facilities compliant with USFDA and EU-GMP standards. www.orchidpharma.com

About Pharmasyntez group

Pharmasyntez Group is one of the leading Russian biopharmaceutical companies, engaged in research, manufacturing, and distribution of socially significant pharmaceuticals and active pharmaceutical ingredients. The Group operates eight manufacturing facilities across Russia, with annual production exceeding 100 million packages and 2025 consolidated revenue of 50.5 billion rubles. With over 6,000 staff, Pharmasyntez manufactures pharmaceuticals across oncology, hematology, endocrinology, immunology, and cardiology. Its portfolio includes over 320 products, of which over 77% are on Russia's List of Vital and Essential Drugs. Pharmasyntez is the largest investor in the Russian pharmaceutical industry, having invested over 25 billion rubles in production and development. <https://pharmasyntez.com/en/>

Advisors

Sathguru Management Consultants acted as exclusive advisor to Orchid Pharma on the transaction.